Journal for Research in Applied Sciences and Biotechnology

www.jrasb.com

ISSN: 2583-4053

Volume-4 Issue-1 || February 2025 || PP. 19-26

https://doi.org/10.55544/jrasb.4.1.2

Recent Advances in Targeted Therapies for Cancer Treatment

Mr. Kartik Sitaram Bharad[1], Mrs. Shital Tukaram Gaikwad[2], Mr. Badruddin Gaysuddin Khan[3], Mr. Shaikh Suleman A.R.[4] and Dr. Gajanan Sanap[5]

[1,2,3,4,5]Department of Pharmaceutics, LBYP College of Pharmacy, Pathri, Phulambri, Chhatrapati Sambhajinager, Maharashtra, INDIA

[1]Corresponding Author: kartikbharad218@gmail.com

ORCiD

https://orcid.org/0009-0008-0759-1743

www.jrasb.com || Vol. 4 No. 1 (2025): February Issue

Received: 01-01-2025	**Revised:** 08-01-2025	**Accepted:** 13-01-2025

ABSTRACT

Recent advances in understanding the birth mechanisms underpinning cancer development have driven the design of new remedial approaches, nominated 'targeted curatives', that widely intrude with motes or pathways involved in excrescence growth and progression. Inactivation of growth factors and their receptors on excrescence cells as well as the inhibition of oncogenic tyrosine kinase pathways and the inhibition of motes that control specific functions in cancer cells constitute the main rational bases of new cancer treatments acclimatized for individual cases. Small-patch impediments and monoclonal antibodies are major factors of these targeted approaches for a number of mortal malice. As the studies of the biomolecular features of cancer progress, new instigative strategies have arisen, similar as targeting cancer stem cells that drive excrescence relapses or the picky induction of apoptosis in nasty cells. This composition primarily focuses on the birth bases of the new cancer medicines and summarizes their mechanisms of action, the clinical substantiation of their anti-cancer effectiveness as well as the explanation for their use in clinical practice.

Keywords- Targeted cancer therapies, Precision oncology, Molecularly targeted drugs, Immunotherapy advancements.

I. INTRODUCTION

Globally, cancer continues to rank among the top causes of illness and death. Conventional treatment methods, such as radiation and chemotherapy, frequently harm both healthy and malignant cells. Recent developments in targeted medicines have fundamentally altered the way that cancer is treated by enabling more focused interventions that target certain biological targets linked to the disease.[1]

Tumor pathogenesis is significantly impacted by defects in the mechanisms underlying programmed cell death (apoptosis), which enable neoplastic cells to live longer than would be expected, undermine the need for exogenous survival factors ,protect against hypoxia and oxidative stress the tumor mass grows, and provide time for cumulative genetic changes that deregulate cell proliferation, interfere with differentiation, promote angiogenesis, and increase cell motility and invasiveness as the tumor progresses[2]. Apoptosis defects allow genetically unstable cells to survive, which creates opportunities for the selection of increasingly aggressive clones. Similarly, defects in DNA repair and chromosome segregation typically cause cell suicide as a defense mechanism for eliminating genetically unstablecells[3].

All paths ultimately lead to apoptosis when it comes to the effective nonsurgical elimination of cancer cells. When effective, almost all cytotoxic anticancer medications now used in clinical settings cause malignant cells to undergo apoptosis. While nucleosides,

Journal for Research in Applied Sciences and Biotechnology

www.jrasb.com

ISSN: 2583-4053

Volume-4 Issue-1 || February 2025 || PP. 19-26

https://doi.org/10.55544/jrasb.4.1.2

DNA-damaging agents, and microtubule binding medications are valuable tools in the fight against cancer, a new class of targeted therapeutics may soon be available thanks to tactics that have been developed from a better understanding of the molecular mechanisms underlying the phenomenon of apoptosis. Proteases called" caspases," for cysteine aspartyl specific proteases, are responsible for apoptosis.[4]

II. BIOLOGY OF TARGETED THERAPY

These medications have an impact on cells (such as bone marrow, gastrointestinal epithelium, and hair). In contrast, a targeted treatment prevents cancer cells from proliferating by interfering with particular molecules required for the creation and progression of excrescence (Figure 2).[5] While some of these motes might be seen in healthy apkins, excrescences usually have them displaced or overexpressed. Among the most effective targeted treatments were antibodies that were made against the The main mechanism of action of conventional cytotoxic chemotherapy is the suppression of cell division (Figure 1). Cluster of isolation 20 (CD20), CD33, and CD52 are labels seen on leukemia and carcinoma cells, as well as other rapidly dividing cells.[6]Targeting this patch impacts overall susceptible function because CD20 is also found on normal lymphoid cells. This finding has resulted in the use of rituximab, also known as Rituxan, an antiCD20 monoclonal antibody, to treat non-Hodgkin's cancer and autoimmune diseases such rheumatoid arthritis[7] [8].



Figure1: In these figures show the dividation of cancers cell.

mechanisms of traditional chemotherapy. These medications target cells that divide quickly, including cancer cells as well as healthy apkins (such as hair, gastrointestinal epithelium, and bone bones). By disrupting DNA base pairing, alkylating agents prevent DNA replication and create beachfront breaks. Inhibitors of topoisomerase facilitate DNA uncoiling. Cell division depends on microtubule activity, which is disrupted by vinca alkaloids and taxanes. Antimetabolites prevent the structure and use of nucleic acids required for DNA replication.[9] When treating solid excrescences (such bone, lung, and colorectal cancers), the molecular pathways that are most frequently addressed include vascular endothelial growth factor (VEGF), HER2/neu, and the epidermal growth factor receptor (EGFR, also known as HER1). (Fig. 2) Through ligand binding and negativity

Similar processes can be suppressed in a number of ways, such as by enclosing receptor-list locations (thereby excluding ligand list), blocking receptor signaling within the cancer cell, snooping with downstream intra cellular motes, or chemicals that adhere to specific receptor spots on cells. Monoclonal antibodies, which are large (average molecular weight of approximately 150,000 Da) and generally water soluble, similar to ligands and receptor-binding disciplines, target the extracellular components of these pathways. Receptor signaling can be blocked and intracellular molecules downstream can be interfered with by small patch barriers, which typically have a molecular weight of 500 Da.[10]



Figure 2: In these figures show the solid tumor in normal cell.

Cell Type, instead, on typical, ugly, and colorful apkins. For example, CD20 is found in both normal and excrescence-associated vas culature, but VEGFR is found in both. Not shown are downstream intracellular signaling molecules, some of which are the target of tiny patch obstructions. Certain medications, such as dasatinib (Sprrycel), imatinib (Gleevec), sunitinib (Sutent), and sorafenib (Nexavar), have several targets. Targeted curative mechanisms. Not all of the molecular targets in this figure are overexpressed in one particular way, and the majority are not shown. (EGFR = epithelial growth factor receptor; VEGFR = vascular endothelial growth factor receptor; VEGF = vascular endothelial growth factor; CD = cluster of isolation; BCR-ABL = breakpoint cluster region-Abelson.)

ISSN: 2583-4053

Volume-4 Issue-1 || February 2025 || PP. 19-26

https://doi.org/10.55544/jrasb.4.1.2

Multiple excrescence types contain EGFR, which aids in the migration, irruption, and proliferation of cancer cells.10. Since EGFR is also found in healthy epithelial tissue, such as skin and mucosa, EGFR suppression can result in serious gastrointestinal and dermatological disorders (Figure 3). Notably, the onset of a rash appears to be a sign that the treatment may be effective in many patients.[11] [12] In extreme situations, dermatological toxins may cause the EGFR asset to be terminated and equivalent actions to topical or systemic antibiotics, topical retinoids, or topical steroids may be taken.[13]Additionally, upto.



Figure 3: Side effect of cancer treating drugs pour or acne formation on skin

50% of patients on EGFR inhibitors experience diarrhea. Like loperamide (Imodium), this toxin is tone-limited in the majority of instances and responds to typical treatment. Twelve Severe diarrhea can occasionally have a substantial impact. loss and may endure parenteral fluid treatment.[14]

In patients treated with cetuximab (Erbitux), a monoclonal antibody that targets the epidermal growth factor receptor, acne form rash ap pearson (A) the face and (B) the reverse. 2. Byinhibitingangiogenesis— the production of new blood vessels from pre-existing vasculature—VEGF targeting restricts the growth of cancer. Angiogenesis is a critical mechanism in the initiation and spread of cancer. Excrescences cannot extend more than 2 to 3 mm past the vasculature in the absence of new blood vessel conformation.[15]Targeting VEGF may potentially improve the administration of other chemotherapeutic drugs by homogenizing the vascular within an excrescence.[16]Nevertheless, damage to healthy blood vessels can also result in comparable symptoms as bleeding, thrombosis, hypertension, and proteinuria due to variations in glomerular capillaries[8] For example, bevacizumab, often known as Avastin, is an anti-VEGF monoclonal antibody that is authorized for the treatment of non-small cell.

Life-hanging hemoptysis rates were unacceptable in clinical trials involving cases with scaled cell histology.[16] [5]Similarly, because bevacizumab has been linked to higher rates of postoperative hemorrhage and other problems, it should be stopped for at least eight weeks following surgery in patients with colorectal cancer.[17]Targeted treatment has occasionally resulted in genuinely adapted treatment. The monoclonal antibody trastuzumab (Herceptin) targets HER2/neu, a molecular target associated with EGFR that is over expressed in about25% of bone cancercases.[18]Trastuzumab is only administered when HER2/neu overexpression is demonstrated in excrescence tissue since it is ineffective in the 75% of bone cancer patients that do not overexpress HER2/neu. EGFR targeting in situations [19] [20]

It work swell against malignancies that heavily rely on the EGFR signaling system, such as non-small cell lung cancer Similar molecular profiling is not new to the area of cancer, and this particularity is most likely to occur in Asian women who do not smoke and have bron chioloalveolar-type excrescences.[20] For many years, only the two thirds of bone cancer cases with excrescences expressing estrogen or progesterone receptors were treated with the hormone receptor modulator tamoxifen (Nolvadex, a brand no longer available in the United States)[21] However, molecular biology is not always associated with therapy efficacy[20]. The level of EGFR expression in the excrescence has no bearing on the effectiveness of cetuximab (Erbitux), an anti-EGFR monoclonal antibody used to treat colorectal cancer.[22]

III. KEY POINTS

Out of the approximately 20 antibodies presently undergoing oncology trials, five have been authorized for use in cancer treatment, and further approvals are expected.

Numerous approaches are being investigated to address the urgent clinical need to improve the effectiveness of anticancer antibodies. Some cancer patients are already benefitting from the combination of chemotherapy and antibody immunotherapy.

The most extensively researched method for enhancing the antitumor action of antibodies is chemically linking them to poisons or radionuclides. Bexxar (tositumomab; 131iodine) and Zevalin (ibritumomab tituxetan; 90yttrium), two anti-CD20 radioimmunoconjugates, are awaiting regulatory clearance, whereas Mylotarg's anti-CD33–calicheamicin conjugate is currently authorized for cancer treatment.

The in vivo antitumor activity of at least four antitumor antibodies, such as trastuzumab (Herceptin) and rituximab (Rituxan), depends on interactions between antibody Fc sections and their Fcγ receptors. Point mutations in Fc that boost binding to FcγRIII and, alternatively, cellular engineering of antibody production hosts to change antibody glycoforms have both been shown to promote tumor-cell death in vitro. The systemic toxicity of cytotoxic chemotherapy and traditional radioimmunotherapy may be significantly decreased by pre-targeting prodrugs and radionuclides to tumors, respectively. For pre- targeting techniques to provide cancer patients meaningfully new therapy choices, they must overcome a number of lingering challenges.

ISSN: 2583-4053

Volume-4 Issue-1 || February 2025 || PP. 19-26

https://doi.org/10.55544/jrasb.4.1.2

Alternative and perhaps complimentary approaches to target tumors include targeting the neovasculature of the tumor and angiogenic growth factors (like VEGF) and receptors. Phase III oncology studies are now underway for bevacizumab (Avastin), a humanized anti-VEGF antibody.

In recent years, doxorubicin and daunorubicin liposomal formulations have been authorized for the treatment of Kaposi's sarcoma. These liposomes may be precisely targeted to tumors by attaching antibody fragments to their surface.

To boost the antitumor immune response, antibody–cytokine fusion proteins, also known as immunocytokines, produce high intratumor cytokine concentrations. In a syngeneic mouse tumor model, preexisting metastases were eradicated by an immunocytokine including IL-2, which bodes well for ongoing clinical trials involving two distinct immunocytokines.

In vivo, lethal agents including immune effector cells, radionuclides, medications, and poisons may be delivered to tumor cells selectively using bispecific antibodies that bind two distinct antigens. Future clinical success with bispecific antibodies is likely to depend on a better understanding of the disappointing results of clinical trials as well as the development of potent new manufacturing technology for these intricate molecules. [23]



IV. TARGETED ANTICANCER THERAPIES USING ANTIBODIES

Because therapeutic antibodies may attach to primary and metastatic cancer cells with excellent specificity, they have emerged as a key tactic in clinical oncology.

Affinity and produce anticancer effects by targeted delivery of radiation or cellular toxins (conjugated antibodies), complement-mediated cytolysis, and antibody-dependent, cell-mediated cytotoxicity (naked antibodies).[24]A number of reasons contributed to the early failure of mouse monoclonal antibodies to cure human tumors, including a lack of focus in target selection that resulted in the discovery of target antigens that were not essential. for cancer cell survival and progression; inadequate tumor cell penetration of antibodies; limited effectiveness in creating radioisotope and toxin conjugates; low overall efficacy of naked mouse antibodies as anticancer medicines; With the creation of human antimouse antibodies (HAMAs), which prohibits the need for many dosage regimens[25].

Recombinant DNA technology was used in antibody creation in the early 1980s to lessen the antigenicity of monoclonal antibodies produced from mice and other rodents. Chimeric antibodies were created wherein the immunoglobulin genes were transgenic ally fused to unite the constant domains of the human IgG molecule with the mouse variable sections; engineered hybridomas and CHO cells were used to make the chimeric monoclonal antibodies[23].

The HAMA reactions were considerably decreased but not entirely eliminated by the application of chimeric antibodies. Even though a number of Although chimeric antibodies were approved by regulators, humanized antibodies were needed for some targets in order to obtain the right dosage. Deimmunized antibodies with variable domains genetically linked to human IgG and primatized antibodies with a chimeric antibody structure of human and monkey that decreased immunogenicity and allowed for continuous repeated dosing and long-term therapy were the next steps after the development of partially humanized antibodies, which further decreased or eliminated the HAMA responses[23].

The effectiveness and toxicity of anticancer antibody therapy have been greatly increased by these contemporary antibody design and deimmunization methods. Tics The effectiveness of anti-cancer antibody medications has increased due to the conjugation of radioisotopes, small-molecule cytotoxic medicines, and protein toxins to the targeted antibodies as well as the improvement of effector function of antibody-dependent cellular cytotoxicity. One of the biggest challenges in the creation of therapeutic antibodies for cancer has been toxicity[23]. Significant adverse effects, such as dyspnea from pulmonary toxic effects and sporadic central and peripheral nervous system complications, might result from cross-reactivity with normal tissues.

Impaired liver function, renal damage, and even unanticipated severe side effects such the damage to the heart muscle brought on by trastuzumab usage. Bone marrow suppression can also result from radio immunotherapy using isotopic-conjugated antibodies. Two of the nine anticancer antibodies available on the global market are conjugated with radioisotopes, and one is conjugated to a complex natural product toxin, as Table 3 illustrates. Conjugation approaches, which have employed arrange of techniques to combine the isotope, toxin, or cytotoxic agent to the antibody, were developed to increase the effectiveness of antibody treatment.[26]

ISSN: 2583-4053

Volume-4 Issue-1 || February 2025 || PP. 19-26

https://doi.org/10.55544/jrasb.4.1.2

V. THE NEXT GENERATION OF CANCER TREATMENT

Due in part to their lack of specificity, many of the conventional cancer therapies mentioned above have serious adverse effects. New Methods are being created to enhance existing conventional therapy and provide better care for cancer patients. Monoclonal antibodies and small molecule inhibitors are the two kinds that are presently under development.[24] The primary function of small molecule inhibitors is to block kinases and stop the activation of pathways that are dysregulated in cancer. Gleevec, a small molecule inhibitor used to treat chronic myeloid leukemia (CML), has shown to be the most effective to far. Gleevec was created to target the aberrant protein known as BCR-ABL (breakpoint cluster region- Abelson protooncogene), which is produced when chromosomes shift and cause the illness. Numerous other small molecule inhibitors have been developed and will be included in this study. Monoclonal antibodies are the second class of targeted cancer therapies.They work by interfering with the interactions between the ligand and the receptor, either by the antibody blocking the contact site or by mast removing the protein from the body[27]. A mutation on the targeted protein is one possible method that people may become resistant to monoclonal antibody treatments. If The antibody will become ineffective and unable to attach to its intended protein target if this mutation takes place in the area that the antibody recognizes. This is one of the reasons why the majority of therapeutic strategies are created with several medications or a certain order for drug administration.

Spyrcel (dasantinib), for instance, is only given to patients who have become resistant to Gleevec (imatinib mesylate). Only after a patient becomes resistant to the monoclonal antibody Herceptin (trastuzumab) is Tykerb (lapatinib), a small molecule inhibitor, given.It's crucial to remember that the effects of monoclonal antibodies and small molecule inhibitors can be readily undone if the medication is completed and given to the patients. The specificity of the treatment makes it possible for the targeted cancer therapy medications to be more accurate and exhibit fewer adverse effects than the conventional cancer therapies, which harm the body's organ systems and immune system. By combining small molecule inhibitors and monoclonal antibodies with conventional cancer treatments, doctors will be able to target the tumor from several angles, improving patient survival. The several kinds of targeted cancer treatment methods will be the main topic of this section. Despite the fact that certain targeted cancer therapy medications can regulate the same mechanism, each medication will often have a therapeutic effect on a certain form of cancer. When feasible, the discussion that follows will concentrate on monoclonal antibodies as well as small molecule inhibitors for every targeted protein. Although monoclonal antibodies may be made to target secreted or plasma membrane proteins, their inability to effectively penetrate the plasma membrane and enter the cytoplasm prevents them from being utilized to target intercellular proteins.

Therefore, monoclonal antibodies cannot target intercellular proteins like Akt and mTOR; instead, small molecule inhibitors are have a reduced selectivity to target proteins, yet they may still target intercellular proteins by passing across the plasma membrane. Each of these treatments has advantages and disadvantages. However, by identifying molecular and cell alterations specific to particular cancer cells, these treatments ought to be more effective and less harmful to healthy cells and tissue than the existing treatment protocols.[27]

VI. CONCLUSION

Patients with particular cancer types now have new hope thanks to recent developments in targeted medicines, which have completely changed the way that cancer is treated. The future of cancer therapy looks bright, with a shift toward more individualized and efficient therapeutic approaches as research continues to identify new targets and improve current medications. the same research efforts to identify drugs for new therapeutic targets have also emphasized the heterogeneity of the biologic processes underlying cancer. Genetic signatures, activation of kinases, pro-apoptotic and growth factor receptors, as well as ‘stemness’ markers, all represent new fingerprints of malignancies. Therefore, based on the evidence that multiple pro-oncogenic signaling pathways are strongly interactive, new combinatory regimens can be envisioned to target the tumor heterogeneity. In fact, phase I/II studies of bevacizumab in combination with erlotinib for the treatment of NSCLC and metastatic renal cancer, as well as the combined inhibition of EGFR and phosphoinositide 3-kinases (PI3K) in PTEN-mutated tumors, represent, to date, effective approaches using selective agents.[112-114] However, additional criteria for selecting patients are required to treat them with effective customized regimens. The identification of the subsets of patients who will most likely benefit from specific drugs as well as the standardization of treatment duration and production expenses of the new bio-molecular drugs may improve the long-term cost-effectiveness ratio of these treatments. Once these goals are reached, it will be possible to realize the full potential of the targeted cancer therapy.

REFERENCES

[1] Ciavarella S, Milano A, Dammacco F, Silvestris F. Targeted therapies in cancer. BioDrugs. 2010;24(2):77-88. doi:10.2165/11530830-000000000-00000

ISSN: 2583-4053

Volume-4 Issue-1 || February 2025 || PP. 19-26

https://doi.org/10.55544/jrasb.4.1.2

[2] Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol. 1999;17(9):2941-2953. doi:10.1200/jco.1999.17.9.2941

[3] Ionov Y, Yamamoto H, Krajewski S, Reed JC, Perucho M. Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution. Proc Natl Acad Sci U S A. 2000;97(20):10872-10877. doi:10.1073/pnas.190210897

[4] Holly TA, Drincic A, Byun Y, et al. Caspase inhibition reduces myocyte cell death induced by myocardial ischemia and reperfusion in vivo. J Mol Cell Cardiol. 1999;31(9):1709-1715. doi:10.1006/jmcc.1999.1006

[5] Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D. Vascular Endothelial Growth Factor (VEGF) as a Target of Bevacizumab in Cancer: From the Biology to the Clinic. Curr Med Chem. 2006;13(16):1845-1857. doi:10.2174/092986706777585059

[6] Akhtar J, Wang Z, Zhang ZP, Bi MM. Lentiviral-mediated RNA interference targeting stathmin1 gene in human gastric cancer cells inhibits proliferation in vitro and tumor growth in vivo. J Transl Med. 2013;11(1):1-9. doi:10.1186/1479-5876-11-212

[7] Silverman GJ. Anti-CD20 therapy and autoimmune disease: Therapeutic opportunities and evolving insights. Front Biosci. 2007;12(6):2194-2206. doi:10.2741/2222

[8] Boner G, Cox AJ, Kelly DJ, et al. Does vascular endothelial growth factor (VEGF) play a role in the pathogenesis of minimal change disease? Nephrol Dial Transplant. 2003;18(11):2293-2299. doi:10.1093/ndt/gfg372

[9] Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the groupe d'etude des lymphomes de l'adulte. J Clin Oncol. 2005;23(18):4117-4126. doi:10.1200/JCO.2005.09.131

[10] Mendelsohn J, Baselga J. Epidermal Growth Factor Receptor Targeting in Cancer. Semin Oncol. 2006;33(4):369-385. doi: 10.1053/j.seminoncol.2006.04.003

[11] Mohamed MK, Ramalingam S, Lin Y, Gooding W, Belani CP. Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer. Ann Oncol. 2005;16(5):780-785. doi:10.1093/annonc/mdi157

[12] Park J, Park BB, Kim JY, et al. Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer. Clin Cancer Res. 2004;10(13):4383-4388. doi:10.1158/1078-0432.CCR-04-0189

[13] Agero ALC, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol. 2006;55(4):657-670. doi:10.1016/j.jaad.2005.10.010

[14] Hidalgo BM, Siu LL, Nemunaitis J, et al. Jco.2001.19.13.3267 (1). 2019;19(13):3267-3279.

[15] Cardones A, Banez L. VEGF Inhibitors in Cancer Therapy. Curr Pharm Des. 2005;12(3):387-394. doi:10.2174/138161206775201910

[16] Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22(11):2184-2191. doi:10.1200/JCO.2004.11.022

[17] Hurwitz H, Saini S. Bevacizumab in the Treatment of Metastatic Colorectal Cancer: Safety Profile and Management of Adverse Events. Semin Oncol. 2006;33(SUPPL. 10):26-34. doi:10.1053/j.seminoncol.2006.08.001

[18] Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, Mcguire WL. Correlation Amplification.

[19] Bast J, Ravdin P, Hayes DF, et al. 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19(6):1865-1878. doi:10.1200/jco.2001.19.6.1865

[20] Pierre Amarenco, Julien Bogousslavsky, Alfred Callahan 3rd, Larry B Goldstein, Michael Hennerici, Amy E Rudolph, Henrik Sillesen, Lisa Simunovic, Michael Szarek, K M A Welch, Justin A Zivin SP by AR in CL (SPARCL) I. 需要引用的霍奇金第二肿瘤new England Journal. N Engl J Med. 2011;365:687-696.

[21] Calvo E, Baselga J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol. 2006;24(14):2158-2163. doi:10.1200/JCO.2006.06.5961

[22] Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol. 2005;23(9):1803-1810. doi:10.1200/JCO.2005.08.037

ISSN: 2583-4053

Volume-4 Issue-1 || February 2025 || PP. 19-26

https://doi.org/10.55544/jrasb.4.1.2

[23] Ross JS, Gray K, Gray GS, Worland PJ, Rolfe M. Anticancer antibodies. Am J Clin Pathol. 2003;119(4):472-485. doi:10.1309/Y6LPC0LR726L9DX9

[24] Milenic D. Monoclonal Antibody-Based Therapy Strategies: Providing Options for the Cancer Patient. Curr Pharm Des. 2005;8(19):1749-1764. doi:10.2174/1381612023393963

[25] Reilly RM, Sandhu J, Alvarez-Diez TM, Gallinger S, Kirsh J, Stern H. Problems of Delivery of Monoclonal Antibodies: Pharmaceutical and Pharmacokinetic Solutions. Clin Pharmacokinet. 1995;28(2):126-142. doi:10.2165/00003088-199528020-00004

[26] Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med. 2002;43(5):693-713.

[27] Ritchie M, Tchistiakova L, Scott N. Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates. MAbs. 2013;5(1):13-21. doi:10.4161/mabs.22854.

[28] Pranali Hatwar, Pallavi Dandge, Pravin Jagtap, Swapnil Gaikwad, Pranali Jadhav, Vaishnavi Sonawane and Dr. Gajanan Sanap. Formulation and Evaluation of solid perfume. World Journal of pharmaceutical. Volume 13, Issue 13,1338-1360.

[29] Akash Haribhau Thengade, Rajeshwari K. Thokal and Gajanan S. Sanap. A REVIEW ON HYDROTROPY: A SOLUBILITY ENHANCING TECHNIQUE World Journal of Pharmaceutical Research SJIF Impact Factor 8.084. Volume 12, Issue 5, 1965-1978

[30] Vaishnavi Mohanrao Sonawane, Pranali Hatwar and Dr. Gajanan Sanap. PROTEIN FIBER IN DRUG DELIVERY SYSTEM. World Journal of Pharmaceutical Research SJIF Impact Factor 8.084. Volume 12, Issue 22, 785-802.

[31] Akash N. Thorat, Nakul P. Kathar, Dr. Gajanan S. Sanap and Manoj S. Bodkhe. REVIEW: BILAYER TABLET IS A NEW APPROACH. WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES. SJIF Impact Factor 7.632 Volume 12, Issue 5, 1028-1047

[32] Ganesh Rajendera Badak, Shubhangi Manikpuriya and Dr. Gajanan S. Sanap. REVIEW: TRANSFEROSOMES: A VESICULAR TRANSDERMAL DELIVERY SYSTEM World Journal of Pharmaceutical Research SJIF Impact Factor 8.084 Volume 12, Issue 5, 2174-2187.

[33] Mr. Vikas Bankar, Mr. Pratik Dhone, Mr. Shahrukh Sayyad, Ms. Nikita Khadke, Ms. Aditi Gawai, Mr. Suleman Shaikh and Dr. Gajanan Sanap. FORMULATION AND EVALUATION OF POLY HERBAL ANTI INFLAMMATORY Tablet WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES SJIF Impact Factor 8.025. Volume 13, Issue 7, 1057-1073

[34] Abhijit Kumbhakar, Mr. Shaikh Suleman, Dr. Rana Zainuddin Ahmed, Mr. Kale Nitin. Topical Fibronectin Improves Wound Healing in Postmastectomy breast Cancer Radiation Therapy. International Journal of Scientific Research in Science and Technology